EGFR Polymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis

Tyrosine kinase inhibitor- (TKI-) based therapy revolutionized the overall survival and the quality of life in non-small-cell lung cancer (NSCLC) patients that have epidermal growth factor receptor (EGFR) mutations. However, EGFR is a highly polymorphic and mutation-prone gene, with over 1200 single...

Descripción completa

Detalles Bibliográficos
Autores principales: Jurisic, Vladimir, Vukovic, Vladimir, Obradovic, Jasmina, Gulyaeva, Lyudmila F., Kushlinskii, Nikolay E., Djordjević, Nataša
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104312/
https://www.ncbi.nlm.nih.gov/pubmed/32256580
http://dx.doi.org/10.1155/2020/1973241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7104312/
https://www.ncbi.nlm.nih.gov/pubmed/32256580
http://dx.doi.org/10.1155/2020/1973241

Ejemplares similares